Who
Catherine A. Sohn
Director
Company insider
Files Form 4 as: Director, Altimmune; Director, Maze Therapeutics; Director, Jazz Pharmaceuticals; Director, Lifecore Biomedical; Director, Axcella Health; Director, Rubius Therapeutics; Director, Palisade Bio.
In numbers
- Trades disclosed
- 124
- Buys
- 5
- Sells
- 15
- Bought
- $84K
- Sold
- $5.8M
- Companies
- 7
- Companies where not an officer
- 7
- First trade
- 9 Aug 2012
- Last trade
- 1 May 2026
- Last filed
- 1 May 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 1 May 2026filed 1 May 2026 | ALT Altimmuneoption or derivative · Biotechnology | SEC FORM 4 Code A | —48,800 at $0.00 | filing |
| 1 May 2026filed 1 May 2026 | ALT Altimmuneoption or derivative · Biotechnology | SEC FORM 4 Code A | —48,800 at $0.00 | filing |
| 7 Jan 2026filed 8 Jan 2026 | MAZE Maze Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —3,281 at $0.00 | filing |
| 7 Jan 2026filed 8 Jan 2026 | MAZE Maze TherapeuticsBiotechnology | SEC FORM 4 Code M | $216K20,744 at $10.42 | filing |
| 7 Jan 2026filed 8 Jan 2026 | MAZE Maze Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —20,744 at $0.00 | filing |
| 7 Jan 2026filed 8 Jan 2026 | MAZE Maze Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,895 at $0.00 | filing |
| 7 Jan 2026filed 8 Jan 2026 | MAZE Maze Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —3,281 at $0.00 | filing |
| 7 Jan 2026filed 8 Jan 2026 | MAZE Maze TherapeuticsBiotechnology | SEC FORM 4 Code M | $30K2,895 at $10.42 | filing |
| 7 Jan 2026filed 8 Jan 2026 | MAZE Maze TherapeuticsBiotechnology | SEC FORM 4 Code M | $34K3,281 at $10.42 | filing |
| 7 Jan 2026filed 8 Jan 2026 | MAZE Maze TherapeuticsBiotechnology | SEC FORM 4 Sold | $1.1M26,920 at $39.11 | filing |
| 7 Jan 2026filed 8 Jan 2026 | MAZE Maze Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —20,744 at $0.00 | filing |
| 7 Jan 2026filed 8 Jan 2026 | MAZE Maze TherapeuticsBiotechnology | SEC FORM 4 Code M | $216K20,744 at $10.42 | filing |
| 7 Jan 2026filed 8 Jan 2026 | MAZE Maze TherapeuticsBiotechnology | SEC FORM 4 Code M | $30K2,895 at $10.42 | filing |
| 7 Jan 2026filed 8 Jan 2026 | MAZE Maze TherapeuticsBiotechnology | SEC FORM 4 Code M | $34K3,281 at $10.42 | filing |
| 7 Jan 2026filed 8 Jan 2026 | MAZE Maze TherapeuticsBiotechnology | SEC FORM 4 Sold | $1.1M26,920 at $39.11 | filing |
| 7 Jan 2026filed 8 Jan 2026 | MAZE Maze Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,895 at $0.00 | filing |
| 6 Jan 2026filed 8 Jan 2026 | MAZE Maze TherapeuticsBiotechnology | SEC FORM 4 Code M | $26K2,493 at $10.42 | filing |
| 6 Jan 2026filed 8 Jan 2026 | MAZE Maze TherapeuticsBiotechnology | SEC FORM 4 Sold | $96K2,493 at $38.62 | filing |
| 6 Jan 2026filed 8 Jan 2026 | MAZE Maze Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,493 at $0.00 | filing |
| 6 Jan 2026filed 8 Jan 2026 | MAZE Maze Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,493 at $0.00 | filing |
News
Altimmune to Present New Data on Pemvidutide in Serious Liver Diseases at AASLD The Liver Meeting® 2026ALT · manilatimes.net · 19 Oct 2026Head to Head Survey: Maze Therapeutics (NASDAQ:MAZE) vs. Cytokinetics (NASDAQ:CYTK)MAZE · dailypolitical.com · 18 Oct 2026
0 headlines in the last 90 days name Catherine A. Sohn; 2 articles from the last 14 days about the 2 companies they traded most, at most three about any one of them.